National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Imipenem/cilastatin/relebactam (Recarbrio®). HTA ID: 20040

Imipenem/cilastatin/relebactam (Recarbrio®) is indicated for the treatment of infections due to aerobic gram-negative organisms in adults with limited treatment options.

 

NCPE Assessment Process Complete
Rapid review commissioned 31/08/2020
Rapid review completed 21/10/2020
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of imipenem/cilastatin/relebactam compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.